Zebrafish xenografts as a fast screening platform for bevacizumab cancer therapy

Despite promising preclinical results, average response rates to anti-VEGF therapies, such as bevacizumab, are reduced for most cancers, while incurring in remarkable costs and side effects. Currently, there are no biomarkers available to select patients that can benefit from this therapy. Depending...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Commun Biol
Κύριοι συγγραφείς: Rebelo de Almeida, Cátia, Mendes, Raquel Valente, Pezzarossa, Anna, Gago, Joaquim, Carvalho, Carlos, Alves, António, Nunes, Vitor, Brito, Maria José, Cardoso, Maria João, Ribeiro, Joana, Cardoso, Fátima, Ferreira, Miguel Godinho, Fior, Rita
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: Nature Publishing Group UK 2020
Θέματα:
Article
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7286887/
https://ncbi.nlm.nih.gov/pubmed/32523131
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s42003-020-1015-0
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια